

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 24, 2009

Date of Report (Date of earliest event reported)

SAFESTITCH MEDICAL, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State of Other Jurisdiction
of Incorporation)

0-19437
(Commission File Number)

11-2962080
(I.R.S. Employer
Identification Number)

4400 Biscayne Boulevard, Suite A-100, Miami, Florida 33137
(Address of principal executive offices) (Zip Code)

(305) 575-4145
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 24, 2009, the Board of Directors (the “Board”) of SafeStitch Medical, Inc., a Delaware corporation (the “Company”), appointed Dr. Chao C. Chen to fill a vacancy on the Board. Mr. Chen will serve until the next annual meeting of the Company’s stockholders or until his earlier death, resignation or removal.

Chao C. Chen, Ph.D., age 56, has served since May 2009 as Chief Operating Officer of UniMed VM, a Taiwanese investment company. From September 2008 to May 2009, Dr. Chen served as Vice President of TaiMed Inc., a Taiwanese investment company, where he was responsible for medical technology investments. From 1983 to 2008 Dr. Chen served in various positions for the Cordis and Ethicon medical device subsidiaries of Johnson & Johnson. In these positions, Dr. Chen was responsible for strategic planning, business integration, product commercialization and new technology research and development.

Item 7.01 Regulation FD Disclosure

On September 29, 2009, the Company issued a press release announcing Mr. Chen’s appointment to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.

The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended. The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Financial Statements and Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated September 29, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SAFESTITCH MEDICAL, INC.

By: /s/ Adam S. Jackson

Name: Adam S. Jackson

Title: Chief Financial Officer

Date: September 29, 2009

Exhibit Index

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release dated September 29, 2009.

SAFESTITCH MEDICAL, INC. APPOINTS DR. CHAO CHEN TO BOARD OF DIRECTORS

MIAMI—(BUSINESS WIRE)—SafeStitch Medical, Inc. (OTCBB: SFES-News) announced today that, on September 24, 2009, the Company's Board of Directors appointed Chao C. Chen, Ph.D. to fill the vacant seat on the Company's Board.

"We are very excited to welcome Dr. Chen, a former executive with Johnson & Johnson, Cordis and Ethicon, to the SafeStitch Board," said Dr. Jane Hsiao, the Company's Chairman. Dr. Hsiao added that "SafeStitch has made significant progress in the development of the AMID Stapler™ and the intraluminal gastroplasty device for GERD and obesity, and Dr. Chen's considerable experience in medical device development and commercialization will be helpful in guiding SafeStitch's strategic launch of these products once we receive regulatory approvals to market them in the U.S. and abroad."

Dr. Chen has served since May 2009 as Chief Operating Officer of UniMed VM, a Taiwanese investment company focused on medical technologies. From September 2008 to May 2009, Dr. Chen served as Vice President of TaiMed Inc., a Taiwanese investment company, where he was responsible for medical technology investments. From 1983 to 2008 Dr. Chen served in various positions for the Cordis and Ethicon medical device subsidiaries of Johnson & Johnson. In these positions, Dr. Chen was responsible for strategic planning, business integration, product commercialization and new technology research and development.

About SafeStitch Medical, Inc.

Miami-based SafeStitch Medical, Inc. is a medical device company primarily developing endoscopic and minimally invasive surgical devices. SafeStitch's product portfolio includes endoscopic gastroplasty devices for bariatric (obesity) surgery and repair of gastroesophageal reflux disorder (GERD), as well as the AMID Stapler™ for hernia repair and skin closure, a standard bite block, an airway bite block and the SMART Dilator™. The Company has also started development of devices for excision and diagnosis of Barrett's esophagus and natural orifice transluminal endoscopic surgery (NOTES). Information about the Company may be found on its website at: www.safestitch.com.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding our product development and commercialization efforts, and our ability to develop and commercialize staplers, intraluminal gastroplasty devices and other surgical instruments, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

Contact:

SafeStitch Medical, Inc., Miami
Dr. Stewart B. Davis, 305-575-4145
